Overview

Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The general aim of the study is to evaluate the anti-tumour activity and the tolerance profile of Pembrolizumab + RT in comparison to cetuximab + RT in patients with locally advanced HNSCC and to explore potential correlations between treatment outcome and the immune landscape.

Phase:

Phase 2

Details

Lead Sponsor:

Groupe Oncologie Radiotherapie Tete et Cou

Treatments:

Antibodies
Cetuximab
Immunoglobulins
Pembrolizumab